Sunitinib With Cabozantinib, Crizotinib, and Savolitinib for Treatment of Advanced Papillary RCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
A Comparison of Sunitinib With Cabozantinib, Crizotinib, and Savolitinib for Treatment of Advanced Papillary Renal Cell Carcinoma: A Randomised, Open-Label, Phase 2 Trial
Lancet 2021 Feb 20;397(10275)695-703, SK Pal, C Tangen, IM Thompson, N Balzer-Haas, DJ George, DYC Heng, B Shuch, M Stein, M Tretiakova, P Humphrey, A Adeniran, V Narayan, GA Bjarnason, U Vaishampayan, A Alva, T Zhang, S Cole, M Plets, J Wright, PN LaraFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.